Bell Potter names the best ASX 200 shares to buy in FY26

The broker has good things to say about these shares.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With the new financial year just days away, now could be an opportune time to think about making some new additions to your investment portfolio.

To help you narrow down your options, let's take a look at three ASX 200 shares that Bell Potter has named among its top picks for FY 2026. They are as follows:

A group of businesspeople clapping.

Image source: Getty Images

JB Hi-Fi Ltd (ASX: JBH)

Bell Potter thinks that retail giant JB Hi-Fi could be an ASX 200 share to buy in the new financial year.

It likes the company due to its estimated 27% market share and its position as Australia's leading technology destination.

The broker believes the latter leaves its well-placed to benefit from an AI driven upgrade cycle. It advised:

We view the retailer as being able to support a higher multiple as we see a sizable upside from the AI driven upgrade cycle/replacement cycle of devices purchased during COVID-peak and given the similarities of JBH and other low gross margin yet high-earnings quality retailers globally.

Bell Potter has a buy rating and $114.00 price target on its shares.

Telix Pharmaceuticals Ltd (ASX: TLX)

Another ASX 200 share to be given the thumbs up by the broker is radiopharmaceuticals leader Telix.

It highlights that its lead product, Illuccix, continues to deliver increasing revenues as the market for PSMA PET expands and as it takes share in its key market in the United States.

Commenting on its positive view of the stock, the broker adds:

We expect average selling price will largely be preserved as the company switches most of its Medicare outpatient client base to the recently approved Gozellix format from 1 October 2025 when the refresh on the pass through pricing is expected to come to bear. Elsewhere, we anticipate the approval of Zircaix in 3Q25 for the imaging of clear cell renal cell carcinoma (ccRCC). Additional short term catalysts include interim data from the PROSTACT Global trial regarding safety and dosimetry from the 30 patient run in study.

Bell Potter has a buy rating and $34.00 price target on Telix's shares.

WiseTech Global Ltd (ASX: WTC)

Finally, this leading provider of software solutions to the global logistics services industry could be an ASX 200 share to buy in FY 2026 according to the broker.

It notes that its shares have pulled back recently due to corporate governance issues around the behaviour of founder Richard White and delays to new product launches. However, it feels the dark clouds are clearing and it will be onwards and upwards for WiseTech Global. It explains:

In our view, however, both issues will progressively fade into the background as a new board and management team are established and CTO is released in FY26. There is also a boost to revenue and earnings to come from a recently announced acquisition – e2Open – and this neatly fills any gap from the delay in launch of new products. Lastly, the stock has underperformed peers like Technology One (TNE) and Xero (XRO) and we now expect relative outperformance as the issues subside.

Bell Potter has a buy rating and $122.50 price target on its shares.

Motley Fool contributor James Mickleboro has positions in Technology One, WiseTech Global, and Xero. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Technology One, Telix Pharmaceuticals, WiseTech Global, and Xero. The Motley Fool Australia has positions in and has recommended WiseTech Global and Xero. The Motley Fool Australia has recommended Jb Hi-Fi, Technology One, and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Broker written in white with a man drawing a yellow underline.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Focused man entrepreneur with glasses working, looking at laptop screen thinking about something intently while sitting in the office.
Broker Notes

Buy, hold, sell: BHP, CBA, and Rio Tinto shares

Morgans has been running the rule over these giants.

Read more »

Two workers working with a large copper coil in a factory.
Broker Notes

Does Macquarie rate BHP shares a buy, hold or sell right now?

What's the verdict on this week's operational update?

Read more »

A young African mine worker is standing with a smile in front of a large haul dump truck wearing his personal protective wear.
Broker Notes

This ASX gold stock could jump by 45%, brokers say

This company has big expansion plans.

Read more »

Engineer looking at mining trucks at a mine site.
Broker Notes

What are the top picks in the ASX lithium sector right now?

A recent pullback in share prices could be creating opportunities.

Read more »

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Broker Notes

Macquarie tips three ASX finance companies to return better than 30%

These finance stocks could be worth a look.

Read more »

A miner shakes hands with a businessman or banker inside an underground mine setting.
Broker Notes

A miner and an energy company to buy according to Macquarie

The broker is bullish on these two companies.

Read more »

A businessman holds his hand to his wide-open yawning mouth as he closes his eyes and makes a funny face while he gives a wholehearted yawn.
Broker Notes

How much could ResMed shares rise according to Morgans?

Current share price weakness could be an opportunity.

Read more »